Study wrapper · #972
Weight management treatment in obesity.
Rubio-Herrera MA, Mera-Carreiro S Medicina clinica. 2025.
DOI: 10.1016/j.medcli.2025.107152PubMed: 40865172
SupportedReviewMentions: SemaglutideMentions: TirzepatideMentions: CagrilintideMentions: Retatrutide
Editor's note
A clinical review of obesity pharmacotherapy covering approved and investigational agents. Multiple tracked peptides appear, with reported weight-loss ranges of roughly 15 to 25 percent for the newer combinations and triple agonists. Landscape context rather than primary evidence.
Plain-language abstract
This review surveys current and emerging weight-management drugs, including semaglutide, tirzepatide, cagrilintide, and retatrutide.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026